Market cap
$18 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -68.50 | -14.15 | -25.14 |
| EBIT | -- | -- | 49.63 | 5.58 | -2.38 |
| Net Profit | -37.46 | 47.48 | 32.13 | -4.69 | -148.76 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Aug-25 | Aug-24 |
| EBIT-Margin
| -1,968.63 | -1,874.62 | -2,960.35 | -1,687.36 | -1,251.12 |
| Net Margin
| -- | -- | -3,985.58 | -- | -- |
| Return on equity
| -147.25 | -112.26 | -160.06 | -215.88 | -104.60 |
| Return on Capital
| -143.98 | -110.04 | -- | -211.16 | -101.83 |
| Return on Assets
| -133.86 | -104.10 | -115.45 | -182.50 | -96.98 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.04 | 0.02 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
--
|
-211.16
|
-101.83
|
-118.94
|
-68.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-160.06
Lower than Peers by 179.03
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
-160.06
|
-215.88
|
-104.60
|
-121.26
|
-68.53
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
-115.45
Lower than Peers by 118.31
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
-115.45
|
-182.50
|
-96.98
|
-122.09
|
-68.90
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
-2,960.35
Lower than Peers by 2,976.17
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
-2,960.35
|
-1,687.36
|
-1,251.12
|
-2,967.41
|
-2,891.05
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
-3,985.58
Lower than Peers by 3,993.81
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
-3,985.58
|
-1,686.00
|
-1,248.25
|
-2,946.36
|
-2,846.28
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-0.05
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
-0.05
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-68.50
Lower than Peers by 76.55
Year on year growth in net sales
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
-68.50
|
0.52
|
1.05
|
-0.11
|
-0.65
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
49.63
Higher than Peers by 41.36
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
49.63
|
-105.06
|
13.47
|
9.09
|
-77.31
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
32.13
Higher than Peers by 24.40
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
32.13
|
-105.37
|
13.05
|
8.31
|
-80.51
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
--
|
0.04
|
0.02
|
0.05
|
0.01
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
0.01
|
0.01
|
0.00
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
10.60
Higher than Peers by 8.95
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
10.60
|
2.32
|
7.18
|
8.22
|
35.96
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
10.60
Higher than Peers by 9.40
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
10.60
|
--
|
--
|
8.22
|
35.76
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
--
|
--
|
--
|
--
|
-64.58
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
25.26
Higher than Peers by 3.98
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
25.26
|
24.65
|
33.27
|
77.47
|
79.01
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.03
Lower than Peers by 0.37
Sales / Average Total Assets
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
0.03
|
0.11
|
0.08
|
0.04
|
0.02
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
--
|
84.98
|
129.70
|
304.39
|
389.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
--
|
--
|
0.08
|
222.74
|
173.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
--
|
162,678.93
|
48,588.36
|
2,001.25
|
572.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
--
|
--
|
-48,458.59
|
-1,474.12
|
-9.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
4.00
Lower than Peers by 3.76
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
4.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
-7.22
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
-7.22
|
0.16
|
1.12
|
0.20
|
0.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
18
Lower than Peers by 2,573
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Aug-25
|
Aug-24
|
Aug-23
|
Aug-22
|
|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
|
18
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,591
|
--
|
--
|
--
|
--
|